ADJUTEC PHARMA AS: årsregnskap 2024 vs 2023
Shrank 100% on revenue, stronger earnings, fresh owner capital
registry 2025-06-21; journal 2025 546182
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for ADJUTEC PHARMA AS. Revenue 7.33m NOK → 7 333 NOK (-99.9%). Net result -9.53m NOK → -1.46m NOK. Equity 18.07m NOK → 33.34m NOK.
On the constructive side: operating result improved; net result improved; equity strengthened. Pressures included: revenue fell; current ratio dropped below 1×; payroll up without matching revenue.
Also worth watching: cogs fell. All figures are taken from the published annual accounts for ADJUTEC PHARMA AS.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -13.05m NOK → -2.10m NOK (op. margin -177.9% → -28643.4%). Calculated
-
↑
Net result improved
Net result -9.53m NOK → -1.46m NOK (net margin -130.0% → -19842.1%). Calculated
-
↑
Equity strengthened
Book equity 18.07m NOK → 33.34m NOK (equity ratio 99.9% → 76.8%). Calculated
-
↑
Cash rose
Bank deposits 6.34m NOK → 6.54m NOK (+3.1% YoY). Calculated
-
↑
Owners injected capital
Paid-in equity rose 49.02m NOK → 65.75m NOK (+16.73m NOK). Reported fact
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 7.33m NOK to 7 333 NOK (-99.9% YoY). Calculated
-
↓
Current ratio dropped below 1×
Current ratio 270.37× → -8.75× — short-term liabilities now exceed liquid/current assets on the published lines. Calculated
-
↓
Payroll up without matching revenue
Salary cost 5.91m NOK → 6.95m NOK (81% → 94808% of revenue). Calculated
Things to notice
-
·
COGS fell
COGS / varekostnad 1 NOK → -22.9k NOK (-2290200.0% YoY). Calculated